Ozempic gets India nod: Drug regulator approves Novo Nordisk’s blockbuster diabetes drug

Ozempic, marketed by Novo Nordisk in India, is primarily indicated for the treatment of type 2 diabetes. While it can lead to ...
Healio

Real-world study reveals risks for kidney failure, death for adults with diabetes

Lower eGFRs were associated with higher likelihood of developing kidney failure and death among adults with diabetes, ...

How Pfizer can compete in the obesity space with its Metsera acquisition

Pfizer enters the obesity drug market with its Metsera acquisition, aiming to challenge leaders Eli Lilly and Novo Nordisk.
Pharmabiz

Novo Nordisk announces Ozempic reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Bagsværd, Denmark Saturday, September 20, 2025, 11:00 Hrs [IST] ...

The ‘permanent and life-altering’ side effect millions on fat jabs face – and what you should do NOW to ward it off

FOR many, fat jabs have done a world of good – dulling hunger pangs and banishing maddening “food noise”, causing pounds to ...

Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...
Labiotech.eu

GLP-1 drugs on WHO Essential Medicines List: what’s the impact?

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.
Medical Marketing & Media

Rx Rundown: Eli Lilly, Lila Sciences, Novartis and more

Michael Langer, son of Bob Langer, raised $78 million for T.Rx Capita l, his new venture capital fund. Dualitas Therapeutics raised $65 million in a Series A financing round. AllRock Bio announced a ...
Medscape

Tirzepatide’s Heart Benefit is Similar to Dulaglutide’s

Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of tirzepatide to dulaglutide in CV outcomes.
Caixin Global

In Depth: Lean Times Ahead for Producers of Weight-Loss Drugs

Since 2023, GLP-1 drugs have fueled blockbuster sales: Novo Nordisk’s semaglutide earned $16.35B (weight-loss sales up 78%), and Eli Lilly’s tirzepatide $14.73B (weight-loss sales up 223%) in the ...
Medical Dialogues

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits

Denmark: Novo Nordisk has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...
Kauppalehti

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Ozempic® is the only GLP-1 RA that has proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes3-6. These results provide the first direct comparison of cardiovascular ...